A Phase 1 interventional study of RE104 for Injection in Lactation, sponsored by Reunion Neuroscience Inc. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-12.
Sponsored by Reunion Neuroscience Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Breast Feeding with a site in United States — 44 open to participants now, 49 under way, none of them phase 3. Breast Feeding · United States.
Among the 251 studies in Breast Feeding with a site in United States, this one is the 168th largest by enrollment of the 202 interventional ones that give a count, is one of 19 that started in 2024, is one of 8 in phase 1, and was the 224th registered.
1,082 studies on the registry are indexed under Breast Feeding; 217 are open to participants now.
Browse Breast Feeding studies →44 of the 251 studies in Breast Feeding with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Women only
University of Illinois at Urbana-Champaign · Sites in United States
Ages 21–45 · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
University of Colorado, Denver · Sites in United States
Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 127 Breast Feeding studies recruiting now, 66 (52%) set no upper age limit and 59 (46%) stop at 75 or younger; 53 take children under 18; 76 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 10 · Phase 3 6 · Phase 4 14
First in 2000; this study’s year is marked. 19 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 100 across 845 interventional studies indexed under Breast Feeding.
Median enrollment 83 across the 202 interventional studies, 88 across the 49 observational. Of the 180 that completed or were terminated, 46 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 251 have an industry lead sponsor. The 10 most frequent:
Reunion Neuroscience Inc is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Reunion Neuroscience Inc has 1 study filed under Breast Feeding — fewer than ten, so there is no comparison to draw.
15 of the studies in Breast Feeding with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07176793University of California, DavisPregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes | 2026-12-30 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06107933Johns Hopkins Bloomberg School of Public HealthDevelopmental Impacts of Microplastics Exposure in Early Life | 2026-12-31 |
| NCT05441709Endeavor HealthFurthering Equity Through Infant Feeding EDucation and Support | 2026-12-31 |
| NCT03838536University of North Carolina, Chapel HillSynergistic Activity of Human Milk Nutrients and Infant Cognition | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 251 studies in Breast Feeding with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to obtain data necessary to characterize the elimination of RE104 and metabolites from breastmilk of health lactating volunteers to support a regulatory assessment of when mothers can safely return to breastfeeding following a single-dose of RE104 for Injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single subcutaneous injection of 30 mg RE104 for Injection
Drug: RE104 for Injection
Single, subcutaneous dose of RE104 for Injection
Area under the concentration-time curve from time zero to 24 hours post-dose (AUC0 24) for RE104 and 4-OH-DiPT in plasma and breast milk
Time frame: Through 24 hours postdose
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for RE104 and 4-OH-DiPT in plasma and breast milk
Time frame: Through 168 hours postdose
Maximum observed concentration (Cmax) for RE104 and 4-OH-DiPT in plasma and breast milk
Time frame: Through 168 hours postdose
Time to reach Cmax (tmax) for RE104 and 4-OH-DiPT in plasma and breast milk
Time frame: Through 168 hours postdose
Apparent total body clearance (CL/F) for RE104 in plasma
Time frame: Through 168 hours postdose
Apparent volume of distribution during the terminal phase (Vz/F) for RE104 in plasma
Time frame: Through 168 hours postdose
Apparent terminal elimination half-life (t1/2) for RE104 and 4-OH-DiPT in plasma
Time frame: Through 168 hours postdose
Milk to plasma (M/P) ratio for RE104 and 4-OH-DiPT in breast milk
Time frame: Through 168 hours postdose
Relative infant dose (RID) of RE104 and its active entity 4-OH-DiPT
Time frame: Through 72 hours postdose
Total RID of RE104 and its active entity 4-OH-DiPT
Time frame: Through 168 hours postdose
Incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.
A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug.
Time frame: From dosing through study completion (post-dose follow-up is for 14 days)
Area under the concentration-time curve from time zero to 24 hours post-dose (AUC0 24) for detectable/quantifiable RE104 metabolites in plasma and breast milk
Time frame: Through 24 hours postdose
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for detectable/quantifiable RE104 metabolites in plasma and breast milk
Time frame: Through 168 hours postdose
Maximum observed concentration (Cmax) for detectable/quantifiable RE104 metabolites in plasma and breast milk
Time frame: Through 168 hours postdose
Time to reach Cmax (tmax) for detectable/quantifiable RE104 metabolites in plasma and breast milk
Time frame: Through 168 hours postdose
Apparent terminal elimination half-life (t1/2) for detectable/quantifiable RE104 metabolites in plasma
Time frame: Through 168 hours postdose
Milk to plasma (M/P) ratio for detectable/quantifiable RE104 metabolites in breast milk
Time frame: Through 168 hours postdose
Amount of RE104 and its active entity 4 OH-DiPT excreted into breast milk (Ae) and amount of drug excreted into breast milk relative to dose (Fe)
Time frame: Through 168 hours postdose
Unbound and bound plasma concentrations of the RE104 active entity 4-OH-DiPT.
Time frame: 1, 3 and 8 hours post-dose
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in May 2025, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Luvesilocin
Reunion Neuroscience Inc